JP6342329B2 - Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 - Google Patents

Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 Download PDF

Info

Publication number
JP6342329B2
JP6342329B2 JP2014542865A JP2014542865A JP6342329B2 JP 6342329 B2 JP6342329 B2 JP 6342329B2 JP 2014542865 A JP2014542865 A JP 2014542865A JP 2014542865 A JP2014542865 A JP 2014542865A JP 6342329 B2 JP6342329 B2 JP 6342329B2
Authority
JP
Japan
Prior art keywords
patient
cancer
egfr
hsa
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014542865A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014533960A (ja
JP2014533960A5 (enExample
Inventor
トマ、リオ、フリオ
ピエール、ローラン‐ピュイグ
サンドリーヌ、アンボー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Descartes
IntegraGen SA
Original Assignee
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé et de la Recherche Médicale
Université Paris Descartes
IntegraGen SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique - Hôpitaux de Paris, Institut National de la Santé et de la Recherche Médicale, Université Paris Descartes, IntegraGen SA filed Critical Assistance Publique - Hôpitaux de Paris
Publication of JP2014533960A publication Critical patent/JP2014533960A/ja
Publication of JP2014533960A5 publication Critical patent/JP2014533960A5/ja
Application granted granted Critical
Publication of JP6342329B2 publication Critical patent/JP6342329B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014542865A 2011-11-25 2012-11-23 Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法 Expired - Fee Related JP6342329B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11306568 2011-11-25
EP11306568.4 2011-11-25
EP12306042 2012-08-31
EP12306042.8 2012-08-31
PCT/EP2012/073535 WO2013076282A1 (en) 2011-11-25 2012-11-23 A method for predicting responsiveness to a treatment with an egfr inhibitor

Publications (3)

Publication Number Publication Date
JP2014533960A JP2014533960A (ja) 2014-12-18
JP2014533960A5 JP2014533960A5 (enExample) 2016-01-14
JP6342329B2 true JP6342329B2 (ja) 2018-06-13

Family

ID=47297187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014542865A Expired - Fee Related JP6342329B2 (ja) 2011-11-25 2012-11-23 Ｅｇｆｒ阻害剤による治療に対する応答性を予測するための方法

Country Status (10)

Country Link
US (1) US10400284B2 (enExample)
EP (1) EP2783017B1 (enExample)
JP (1) JP6342329B2 (enExample)
KR (1) KR20140104419A (enExample)
CN (1) CN104160038B (enExample)
AU (1) AU2012342397B2 (enExample)
BR (1) BR112014012495A2 (enExample)
CA (1) CA2856594A1 (enExample)
MX (1) MX2014006182A (enExample)
WO (1) WO2013076282A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2931176A1 (en) * 2013-11-26 2015-06-04 Integragen A method for predicting responsiveness to a treatment with an egfr inhibitor
KR101622454B1 (ko) 2014-03-04 2016-05-18 연세대학교 산학협력단 Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커
EP3131552B1 (en) * 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
EP3000895A1 (en) * 2014-09-26 2016-03-30 Integragen A method for predicting responsiveness to a treatment with an EGFR inhibitor
CN107850599B (zh) * 2015-07-23 2021-02-09 新加坡国立大学 Wbp2与her2作为共预后因子对患者分层以进行治疗
EP3450555B1 (en) * 2016-04-28 2020-11-18 Denka Company Limited Method for determining tolerance of cancer cell to epidermal growth factor receptor inhibitor
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
KR102251864B1 (ko) * 2019-10-18 2021-05-14 지니너스 주식회사 miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물
CN111798918A (zh) * 2020-05-28 2020-10-20 中山大学孙逸仙纪念医院 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法
CN111863159B (zh) * 2020-06-01 2022-02-25 中山大学孙逸仙纪念医院 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法
WO2023165494A1 (en) * 2022-03-01 2023-09-07 Crown Bioscience (Suzhou) Inc. Methods for determining cetuximab sensitivity in cancer patients

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
RU2010120674A (ru) * 2007-10-22 2011-11-27 Шеринг Корпорейшн (US) Полностью человеческие анти-vegf-антитела и способы их применения
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
WO2010015538A2 (en) * 2008-08-05 2010-02-11 F. Hoffmann-La Roche Ag Predictive marker for egfr inhibitor treatment
EP2419522A4 (en) 2009-04-17 2012-10-31 Glen Weiss METHOD AND KITS FOR THE FORECASTING OF THERAPY RESULTS OF TYROSINE CHINESE INHIBITORS
US9051551B2 (en) * 2009-11-24 2015-06-09 The University Of Western Australia Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors
EP2563936B1 (en) * 2010-04-29 2018-03-14 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy

Also Published As

Publication number Publication date
JP2014533960A (ja) 2014-12-18
AU2012342397B2 (en) 2018-04-05
US10400284B2 (en) 2019-09-03
US20140370029A1 (en) 2014-12-18
EP2783017B1 (en) 2018-12-26
BR112014012495A2 (pt) 2017-06-06
MX2014006182A (es) 2014-12-08
CA2856594A1 (en) 2013-05-30
CN104160038B (zh) 2018-06-12
AU2012342397A1 (en) 2014-06-12
CN104160038A (zh) 2014-11-19
KR20140104419A (ko) 2014-08-28
WO2013076282A1 (en) 2013-05-30
EP2783017A1 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
EP2783017B1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
US12077803B2 (en) MicroRNAs as biomarkers for endometriosis
EP2527460B1 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
EP3198028B1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
US20160376661A1 (en) A method for predicting responsiveness to a treatment with an egfr inhibitor
US20120095030A1 (en) Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors
US20150344961A1 (en) Sera Based miRNAs as Non-Invasive Biomarkers in Melanoma
AU2008286335B2 (en) Predictive marker for EGFR inhibitor treatment
AU2008286406A1 (en) Predictive markers for EGFR inhibitor treatment
CA2695247A1 (en) Predictive marker for egfr inhibitor treatment
HK40011172B (en) Micrornas as biomarkers for endometriosis
HK40011172A (en) Micrornas as biomarkers for endometriosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151119

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170602

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170809

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180516

R150 Certificate of patent or registration of utility model

Ref document number: 6342329

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R370 Written measure of declining of transfer procedure

Free format text: JAPANESE INTERMEDIATE CODE: R370

LAPS Cancellation because of no payment of annual fees